Wockhardt shares rallied sharply on Friday, surging 7.87% to hit Rs 1,910.50 after the pharmaceutical company received a major regulatory boost for its breakthrough antibiotic, Zaynich. Notably, the stock has climbed nearly 12% in just the last two trading sessions, reflecting strong investor optimism following the development.
In an exchange filing, Wockhardt announced that the Central Drugs Standard Control Organisation (CDSCO) has approved the import and marketing of its indigenously discovered and developed first-in-class antibiotic, Zaynich (Zidebactam/Cefepime), in India.
